Two Sigma Investments
SLRN

Two Sigma Investments’s ACELYRIN SLRN Stock Holding History

Two Sigma Investments’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-123,470
Closed -$545K – 3321
2024
Q2 		$545K Buy
+123,470
New +$579K ﹤0.01% 2324

Other funds holding SLRN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Two Sigma Investments's SLRN Position: Q3 2024 in Review

Two Sigma Investments sold out of ACELYRIN (SLRN) in Q3 2024, closing a stake of 123,470 shares — an estimated $545K sold.

Two Sigma Investments first reported a position in SLRN in Q2 2024 and held it in 1 quarter. The position peaked at $545K in Q2 2024. 122 funds tracked by Wall St. Rank hold SLRN as of Q3 2024.

  • Two Sigma Investments reported no remaining ACELYRIN position as of Q3 2024 after selling out during the quarter.
  • Two Sigma Investments sold 123,470 ACELYRIN shares in Q3 2024, an estimated $545K.
  • Two Sigma Investments first reported a position in ACELYRIN in Q2 2024 and held it in 1 quarter.
  • Two Sigma Investments's ACELYRIN position peaked at $545K in Q2 2024.
  • 122 funds tracked by Wall St. Rank held ACELYRIN as of Q3 2024.

Based on Two Sigma Investments's 13F filing for Q3 2024, filed 14 Nov 2024.